Eltrombopag(Revolade)

Eltrombopag was first approved by the FDA in November 2008. It targets the thrombopoietin receptor (TPO receptor/c-Mpl), is a prescription medication, and must be used strictly under medical supervision.

Target of Action

Thrombopoietin receptor (TPO receptor / c-Mpl).

Mechanism of Action

Eltrombopag is a platelet growth factor. Its mechanism of action differs from steroids or intravenous immunoglobulin.It works with your body to produce more platelets to compensate for the low platelet count.This in turn helps increase platelet counts and may reduce bruising and bleeding caused by persistent or chronic ITP.

Dosage and Administration

Route and frequency of administration: Eltrombopag is taken orally, once daily.

The dosage of eltrombopag should be adjusted based on the patient’s actual condition.

Please consult a doctor and strictly follow medical advice.

Recommended reading: Dosage and Administration of Eltrombopag

Side Effects

Main risks and warnings: Liver problems.

Common side effects: nausea, diarrhea, upper respiratory tract infection.

Serious side effects: progression of a precancerous blood condition to blood cancer, increased platelet counts and higher risk of blood clots, new or worsening cataracts.

Reference article: Side Effects of Eltrombopag

Use in Special Populations

Pregnancy:

Available data from published case reports and postmarketing experience with eltrombopag use in pregnant women are limited and insufficient to assess drug-associated risks for major birth defects, miscarriage, or adverse maternal or fetal outcomes.

Lactation:

Eltrombopag may cause serious adverse reactions in a breastfed child. Breastfeeding is not recommended during treatment.

Daily Precautions

1. Carefully read the patient information (medication guide) provided by the manufacturer before initiating therapy and each time the prescription is refilled.

2. Risk of hepatic failure: Immediately report symptoms suggestive of jaundice (e.g., yellowing of the skin or eyes), unusual darkening of the urine, unusual fatigue, or right upper quadrant (abdominal) pain to a healthcare provider.

3. Patients with chronic hepatitis C and cirrhosis are at risk of hepatic decompensation when receiving eltrombopag in combination with alpha interferon therapy.

from FDA，2021.10